Catalog No.S7617 Synonyms: ABR-215050
Molecular Weight(MW): 406.36
Tasquinimod is an orally active antiangiogenic agent by allosterically inhibiting HDAC4 signalling. Phase 3.
Purity & Quality Control
Choose Selective HDAC Inhibitors
Click to view more
2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.
|Description||Tasquinimod is an orally active antiangiogenic agent by allosterically inhibiting HDAC4 signalling. Phase 3.|
Tasquinimod inhibits tumor angiogenesis by allosteric inhibition of HDAC4/N-CoR/HDAC3 dependent deacetylation of HIF-1α.  Tasquinimod also targets infiltrating myeloid cells, and modulates local tumour immunity by blocking the interaction between S100A9 and its ligands receptor of advanced glycation end products and Toll-like receptor 4. 
|In vivo||Tasquinimod (30 mg/kg/d p.o.) shows anti-angiogenic activity and thus causes tumor growth inhibition in mice bearing human and rodent prostate cancer models. |
|In vitro||DMSO||81 mg/mL (199.33 mM)|
|Ethanol||11 mg/mL warmed (27.06 mM)|
|In vivo||5% DMSO+30% PEG 300+ddH2O||8mg/mL|
* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT02396368||Withdrawn||Prostate Cancer|Bone-only Metastatic Castration-Resistant Prostate Cancer (CRPC)||Sidney Kimmel Comprehensive Cancer Center||March 2015||Phase 1|
|NCT02159950||Completed||Hormone-Resistant Prostate Cancer|Metastatic Prostate Carcinoma|Recurrent Prostate Carcinoma|Stage IV Prostate Cancer||Roswell Park Cancer Institute|National Cancer Institute (NCI)|Active Biotech AB||January 2015||Phase 2|
|NCT02057666||Terminated||Asian Chemo-naïve Patients With Metastatic Castrate-resistant Prostate Cancer||Ipsen||January 2014||Phase 3|
|NCT01732549||Terminated||Metastatic Castrate Resistant Prostate Cancer||Ipsen||January 2013||Phase 2|
|NCT01743469||Active, not recruiting||Advanced or Metastatic Hepatocellular Cancer|Advanced or Metastatic Ovarian Cancer|Metastatic Renal Cell Cancer|Advanced or Metastatic Gastric Carcinoma||Ipsen||December 2012||Phase 2|
|NCT01513733||Completed||Prostate Cancer||Andrew J. Armstrong, MD|Duke University||January 2012||Phase 1|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.